In this section of the Lung Therapeutics Online Press Kit, you'll find our news releases. The releases are listed in chronological order and are archived by month and year.
Financing will support further development of the Company’s LTI-03 transformative drug technology and the current multi-site clinical trial of orphan drug LTI-01.
LTI-01 addresses unmet needs in a $600+ million global market. Intended to replace costly surgery and ineffective off-label treatments of fibrosis, the drug can provide safer and more cost-effective therapeutic options for CPE/empyema patients and healthcare providers worldwide.
